Dianabol vs LGD-4033
Well Studied vs Moderate Research
avoid Mechanism-based · 64% Both Dianabol and LGD-4033 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.
Molecular Data
Dianabol LGD-4033
Weight 300.44 Da 338.25 Da
Half-life ~4-6 hours ~24-36 hours
Type 17-alpha-alkylated anabolic steroid (C20H28O2) Nonsteroidal selective androgen receptor modulator (C14H12F6N2O)
Key Benefits
Dianabol
01 Rapid and dramatic increases in muscle mass and bodyweight
02 Significant strength gains within the first 1-2 weeks
03 Enhanced nitrogen retention and protein synthesis
04 Improved glycogenolysis and muscular endurance
05 Pronounced muscle fullness and pumps from increased intracellular water and glycogen
06 Effective oral kickstart while waiting for injectable compounds to saturate
07 One of the fastest-acting anabolic compounds available
LGD-4033
01 Strongest SARM for lean muscle mass accrual, with clinical trial data supporting dose-dependent increases in lean body mass
02 Tissue-selective action with minimal stimulation of the prostate and other androgen-sensitive tissues
03 Clinical evidence of improved physical function (leg press strength, stair-climbing speed) in hip fracture patients
04 No aromatization to estrogen (no estrogen-related water retention or gynecomastia at the receptor level)
05 No conversion to DHT (reduced risk of androgenic hair loss and prostate stimulation compared to testosterone)
06 Convenient once-daily oral dosing due to 24-36 hour half-life
07 Phase 2 clinical data available, providing a stronger evidence base than most other SARMs
Side Effects
Dianabol
Significant water retention and bloating (estrogen-mediated)
Elevated blood pressure from fluid retention and increased red blood cell mass
Liver stress with elevated ALT/AST enzymes (dose and duration dependent)
Back pumps (painful lower back cramping during exercise)
Increased appetite
Oily skin and acne
Suppression of endogenous testosterone production (HPTA suppression)
Mild mood changes (increased aggression, irritability, or euphoria)
LGD-4033
Testosterone suppression (dose-dependent; more suppressive than Ostarine at equivalent doses, occurs in most users by week 4-6)
Water retention (non-estrogenic mechanism, typically mild to moderate, contributes to scale weight increase)
HDL cholesterol reduction (dose-dependent lipid impact observed in clinical trials)
Headaches (most common in the first 1-2 weeks, usually transient)
Fatigue or lethargy (related to testosterone suppression, typically becomes noticeable mid-cycle)
Reduced libido (related to HPG axis suppression, severity varies by dose and individual)
Contraindications
Pre-existing liver disease or impaired hepatic function
Active or history of hormone-sensitive cancers (prostate, breast)
Uncontrolled hypertension or significant cardiovascular disease
Elevated hematocrit (above 54%) at baseline
Concurrent use of other hepatotoxic oral steroids (do not stack C17-aa orals)
Pregnancy or potential exposure to pregnant women
Heavy alcohol use (compounded hepatotoxicity risk)
Cholestatic liver conditions or history of drug-induced liver injury
Pre-existing liver disease or elevated liver enzymes at baseline
Hormone-sensitive cancers (prostate cancer or other androgen-driven malignancies)
Pregnancy or potential pregnancy (teratogenic risk from androgen receptor agonism)
Breastfeeding
Age under 25 (incomplete endocrine system maturation and higher risk of HPG axis disruption)
Concurrent use of hepatotoxic medications without medical supervision
Known cardiovascular disease (insufficient long-term safety data for this population)
History of significant lipid abnormalities (LGD-4033 suppresses HDL)
Research Evidence
Dianabol LGD-4033
Status Well Studied Moderate Research
References 5 studies 5 studies
Latest 2017 2018
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.